Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA 2026 Congress

Written by Charlie King | 22 May 2026 | Conference Highlights

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment of RET fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 ASCO Annual Meeting on Friday, May 29, 2026.

The ASCO Annual Meeting and EHA 2026 Congress will feature poster presentations including additional pralsetinib data and data for REZLIDHIA® (olutasidenib) for relapsed or refractory mIDH1-mutated AML. ASCO is held in Chicago and virtually May 29–June 2, 2026; EHA2026 in Stockholm and virtually June 11–14, 2026.

“Having an oral presentation at ASCO as well as multiple additional data presentations at both upcoming medical conferences underscores the continued clinical relevance of our oncology portfolio,” said Raul Rodriguez, Rigel’s President and CEO.

Key Clinical Highlights

Phase 3 AcceleRET-Lung: Pralsetinib met the primary PFS endpoint with significantly greater overall response rate and more durable response vs. standard of care. Deaths: 32 (30.0%) pralsetinib vs. 26 (25.0%) SoC; 8 (7.4%) vs. 0 infection-related.
Phase 1/2 ARROW (RET-altered thyroid cancer): Clinically meaningful and durable responses with manageable safety, consistent with prior reports.
Olutasidenib Phase 2 (R/R mIDH1 AML): Long-term CR/CRh (>12 months) in half of CR/CRh patients without transplant (longest >54 months). Estimated 48-month OS: 74% (95% CI: 51%–88%).
Real-world olutasidenib post-venetoclax (51 charts, 18 physicians): CR/CRh rate 60.8%, CR rate 57%, median response duration 30.3 months.

View the Rigel Pharmaceuticals ASCO 2026 Presentation Schedule HERE.